NO20053189L - HVC-kombinasjonsterapi. - Google Patents

HVC-kombinasjonsterapi.

Info

Publication number
NO20053189L
NO20053189L NO20053189A NO20053189A NO20053189L NO 20053189 L NO20053189 L NO 20053189L NO 20053189 A NO20053189 A NO 20053189A NO 20053189 A NO20053189 A NO 20053189A NO 20053189 L NO20053189 L NO 20053189L
Authority
NO
Norway
Prior art keywords
hvc
combination therapy
hepreceptor
ezrin
interferon
Prior art date
Application number
NO20053189A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053189D0 (no
Inventor
Rupert Donald
Ravshan Inoyatov Ataullakhanov
Original Assignee
Regent Res Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regent Res Llp filed Critical Regent Res Llp
Publication of NO20053189D0 publication Critical patent/NO20053189D0/no
Publication of NO20053189L publication Critical patent/NO20053189L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20053189A 2003-01-27 2005-06-29 HVC-kombinasjonsterapi. NO20053189L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301879.3A GB0301879D0 (en) 2003-01-27 2003-01-27 HCV combination therapy
PCT/GB2004/000330 WO2004067024A2 (fr) 2003-01-27 2004-01-27 Traitement combine pour le vhc

Publications (2)

Publication Number Publication Date
NO20053189D0 NO20053189D0 (no) 2005-06-29
NO20053189L true NO20053189L (no) 2005-08-24

Family

ID=9951908

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053189A NO20053189L (no) 2003-01-27 2005-06-29 HVC-kombinasjonsterapi.

Country Status (13)

Country Link
US (1) US20060067913A1 (fr)
EP (1) EP1587531A2 (fr)
JP (1) JP2006515011A (fr)
KR (1) KR20050101184A (fr)
CN (1) CN1738639A (fr)
AU (1) AU2004208541A1 (fr)
BR (1) BRPI0406985A (fr)
CA (1) CA2511562A1 (fr)
GB (1) GB0301879D0 (fr)
IL (1) IL169322A0 (fr)
MX (1) MXPA05007901A (fr)
NO (1) NO20053189L (fr)
WO (1) WO2004067024A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3191504T2 (ro) 2015-06-01 2018-04-30 Nearmedic International Ltd Peptide derivate din ezrin și compozițiile farmaceutice ale acestora
RU2694906C2 (ru) * 2016-06-01 2019-07-18 Ниармедик Интернэшнл Лимитед Пептиды производные эзрина и фармацевтические композиции на их основе
WO2021198346A2 (fr) 2020-04-01 2021-10-07 Dr. Nesselhut Besitzgesellschaft Mbh Peptide ezrine 1 destiné à être utilisé dans un procédé de traitement de la covid-19
EP4313108A1 (fr) 2021-03-31 2024-02-07 Pantapharm AG Peptide d'ezrine 1 destiné à être utilisé dans un procédé de traitement de syndrome post-covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (fr) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin

Also Published As

Publication number Publication date
CN1738639A (zh) 2006-02-22
GB0301879D0 (en) 2003-02-26
BRPI0406985A (pt) 2006-01-10
US20060067913A1 (en) 2006-03-30
CA2511562A1 (fr) 2004-08-12
EP1587531A2 (fr) 2005-10-26
IL169322A0 (en) 2007-07-04
NO20053189D0 (no) 2005-06-29
AU2004208541A1 (en) 2004-08-12
JP2006515011A (ja) 2006-05-18
WO2004067024A2 (fr) 2004-08-12
KR20050101184A (ko) 2005-10-20
MXPA05007901A (es) 2005-09-21
WO2004067024A3 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
EA200700243A1 (ru) Способы лечения гепатита с
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
WO2006110655A3 (fr) Composes, compositions et methodes de traitement des infections a poxvirus
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ATE473750T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
WO2002042480A3 (fr) Variant du virus de la vaccine modified vaccinia ankara
WO2007041487A3 (fr) Peptides inhibiteurs d'infections virales
PA8744101A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NO20053189L (no) HVC-kombinasjonsterapi.
HK1128622A1 (en) Use of thymosin
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
DK1778271T3 (da) Peptid til behandling af herpesvirusinfektioner
WO2004052905A3 (fr) Derives de nucleoside antiviraux
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
WO2004006848A3 (fr) Polytherapies avec ftc destinees au traitement d'une infection a virus de l'hepatite b
AU2019384793A8 (en) Methods for treating acute HCV
WO2008036157A3 (fr) Traitement prophylactique et thérapeutique d'infections de grippe aviaire chez les animaux

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application